
ASCO DATA REVIEW 2026
July 16, 2026



Breast Cancer

ASCENT-04: In first-line PD-L1 + mTNBC, sacituzumab govitecan plus pembrolizumab showed sustained benefit beyond first progression despite crossover to SG …*now FDA approved.*

ASCENT-03: In first-line mTNBC patients ineligible for PD-1/PD-L1 inhibitors, sacituzumab govitecan demonstrated long-term benefit until the next line of therapy despite crossover to SG…*now FDA approved.*

TROPION-Breast02: In first-line mTNBC, patients ineligible for PD-1/PD-L1 inhibitors, datopotamab deruxtecan improved PFS2, TFST, and TSST, alongside a manageable safety profile …*now FDA approved.*

DESTINY-Breast05: Post-neoadjuvant T-DXd was associated with mostly low-grade, reversible ILD/RP events, though higher ILD rates vs T-DM1 and influenced by region and baseline renal function in HER2+ early breast cancer…*now FDA approved.*

DESTINY-Breast09: In first-line HER2+ mBC, T-DXd plus pertuzumab achieving a durable CR or PR was associated with favorable PFS outcomes and prolonged treatment duration… *now FDA approved.*

SERENA-6: No OS yet by switching to camizestrant.

PersevERA: No benefit for giredestrant vs letrozole in combo with palbo as 1L for HR+HER2- mBC.

Keynote-522: Long-term OS benefit in pembro groups vs placebo group for early-stage TNBC.

GI/GU Cancer

RASolute-302: Daraxonrasib demonstrated statistically significant and clinically meaningful improvements in OS, PFS, and ORR in patients with previously treated metastatic PDAC and was better tolerated than standard chemotherapy (watch for rash, diarrhea, nausea and stomatitis). *May 1, 2026: FDA approved expanded access*

EMERALD-3: First Phase 3 trial to show that combining STRIDE with TACE improves outcomes in embolization-eligible unresectable HCC and supports this approach as a potential new standard treatment option pending longer-term OS follow-up; adding lenvatinib did not increase benefit… *not yet FDA approved*

PROTEUS: perioperative apalutamide + ADT significantly increases the likelihood of a major pathologic response and reduces the risk of future metastatic disease compared with ADT alone in high-risk localized or locally advanced prostate cancer undergoing surgery;) … *not yet FDA approved*

TALAPRO-3: Adding talazoparib (a PARP inhibitor) to enzalutamide plus androgen deprivation therapy (ADT) significantly prolonged radiographic progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations… *not yet FDA approved*

Other noteable studies

FrontMIND: Tafa-Len-R-CHOP significantly prolonged PFS compared with R-CHOP (HR 0.75; 2-year PFS rate, Δ =8.2%) and may become a new standard first-line treatment option for patients with previously untreated high–risk DLBCL and HGBL … *not yet FDA approved.*

MajesTEC-9: Teclistamab monotherapy showed significant PFS (HR 0.29) and OS (HR 0.60) benefit in highly exposed and relapsed / refractory multiple myeloma and may be a new standard of care as early as the second line setting… *not yet FDA approved; approved for 4 prior lines of therapy*

HARMONI-6*: Ivonescimab with chemotherapy significantly improved OS (27.89 vs 23.69 months) in advanced squamous NSCLC as first-line treatment compared with tisleizumab plus chemotherapy… *not yet FDA approved*

LIBRETTO*: Selpercatinib showed a clinically meaningful and statistically significant EFS (24-mo EFS rate of 91.5% vs 61.1%) improvement vs placebo in early-stage RET fusion–positive NSCLC… *not yet FDA approved for the adjuvant treatment of resected stage IB–IIIA RET fusion-positive NSCLC; approved for locally advanced or metastatic RET fusion-positive NSCLC*

SARC041*: Abemaciclib demonstrated a statistically significant improvement in PFS at 9.67 months vs placebo at 1.52 months (HR: 0.39) and may become a new standard of care for patients with advanced dedifferentiated liposarcoma … *not yet FDA approved*

Program Chairs

EDITH A. PEREZ, MD - Breast Cancer
Cornerstone Specialty Network

SUJITH R. KALMADI, MD - GU/GI Cancer
Ironwood Cancer and Research Centers, Phoenix, AZ

ERIC S. SCHAEFER, MD - Other notable studies
Highlands Oncology Group, Fayetteville, AR

cornerstone specialty network™

© 2026 Cornerstone Specialty Network, LLC.
All rights reserved.

P.O. Box 173 - New Hope, PA 18938
v07282026